<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520750</url>
  </required_header>
  <id_info>
    <org_study_id>PALV-03</org_study_id>
    <nct_id>NCT04520750</nct_id>
  </id_info>
  <brief_title>VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita</brief_title>
  <acronym>VALO-2</acronym>
  <official_title>VALO-2: A Multicenter, Phase 3b, Open-Label Treatment Extension Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palvella Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Palvella Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VALO-2 is a multicenter, open-label extension (OLE) study enrolling patients with genotyped&#xD;
      keratin mutations KRT6A, KRT6B and KRT16 who were previously treated with investigational&#xD;
      PTX-022 during the VALO study. The purpose of the OLE study is to investigate long term&#xD;
      exposure to investigational PTX-022 and evaluate safety and efficacy data. A sub-study is&#xD;
      included to evaluate safety and efficacy of patients with genotyped keratin mutations of&#xD;
      KRT6C and KRT17 not previously treated with investigational PTX-022.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>18 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in vital sign measurements from baseline</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in weight measurements from baseline</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in clinical laboratory measurements from baseline</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Activities Scale</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at its worst as assessed by NRS</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Pain Interference Short 6A as assessed by likert scale</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Physical Function as assessed by likert scale</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Severity as assessed by likert scale</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Global Impression of Severity as assessed by likert scale</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pachyonychia Congenita</condition>
  <arm_group>
    <arm_group_label>Open label treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTX-022 QTORIN</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTX-022</intervention_name>
    <description>Safety and Efficacy of PTX-022 in the Treatment of Adults with Pachyonychia Congenita</description>
    <arm_group_label>Open label treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients 18 years or older,&#xD;
&#xD;
          -  Previously completed the VALO protocol, or VALO-2 K6C/17 sub-study, and received&#xD;
             meaningful benefit from investigational PTX-022 as determined by the clinician.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications&#xD;
             or to PTX-022&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emily Cook</last_name>
    <phone>484-253-1463</phone>
    <email>emily.cook@palvellatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pachyonychia Congenita</mesh_term>
    <mesh_term>Nails, Malformed</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

